Dr. Reddy’s To Train 5,000 Professionals In Obesity Care
NiveshIQ
NSE: DRREDDY · Pharma
Dr. Reddy's Laboratories Ltd.
₹1,165.50▲ ₹22.50 (+1.97%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on DRREDDY. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Limited is an integrated pharmaceutical company operating in North America, Europe, India, Russia, and internationally. The company's core business is divided into three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment is a key revenue driver, manufacturing and marketing prescription and over-the-counter finished pharmaceutical products. The PSAI segment provides contract research services and manufactures active pharmaceutical ingredients and steroids. Dr. Reddy's Laboratories has a strong presence in the Indian market and is expanding its operations globally. The company has recently navigated challenges in the weight-loss drug market, but its growth outlook remains positive. With a strong f
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹28,012 Cr +13.50% | ₹32,643 Cr +16.50% | ₹33,700 Cr +3.20% |
| EBITDA Margin | 28.29% | 25.97% | 23.18% |
| Net Profit | ₹5,578 Cr +23.80% | ₹5,725 Cr +2.60% | ₹4,158 Cr -27.40% |
| EPS | ₹66.90 | ₹67.77 | ₹50.41 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Dr. Reddy’s Launches Obesity Care Training Initiative
FDA notes observations at Dr. Reddy's (NYSE: RDY) Mexico drug plant
🔒
+ 3 more stories about Dr. Reddy's Laboratories Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹5, 137 Cr, PAT ₹405 Cr, EPS ₹4.86, EBITDA margin 17.3%. Growth context: revenue QoQ -31.9%, PAT QoQ +82.9%. Street verdict: strong miss, revenue surprise -36.7%, PAT surprise -46.8%.
Management commentary highlights the importance of product launches, approvals, and therapy-mix improvement in driving n...
The company's FY26 performance was marked by revenue of ₹33, 700 Cr, PAT of ₹4, 158 Cr, and an EBITDA margin of 23.2%, w...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for DRREDDY
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track DRREDDY alongside your other holdings
Unlock full DRREDDY research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Dr. Reddy's Laboratories Ltd.?
NiveshIQ detects active intelligence signals for Dr. Reddy's Laboratories Ltd. (DRREDDY) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Dr. Reddy's Laboratories Ltd.?
Dr. Reddy's Laboratories Ltd. operates in the Pharma sector with a market capitalisation of ₹9,545,347.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.